Clinical trials: Astrocytoma
Glioblastoma
Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas
This study was conducted to evaluate the efficacy and safety of depatuxizumab mafodotin (ABT-414) alone or with temozolomide versus temozolomide or lomustine alone in adult participants with recurrent glioblastoma.
- Trial name
- INTELLANCE-2 (NCT02343406)
- Testing
- Depatuxizumab mafodotin, Temozolomide, Lomustine
- Where
- 102 sites in United States, Australia and 19 more
- Volunteers
- 266 people
- Sponsor
- AbbVie
Glioma, Anaplastic Astrocytoma
Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma
Malignant gliomas have a very poor prognosis with median survival measured in months rather than years. It is a disease in great need of novel therapeutic approaches.
- Conditions
- Glioma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma
- Trial name
- NCT03072134
- Testing
- Neural stem cells loaded with an oncolytic adenovirus
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Northwestern University
Glioblastoma Multiforme
A Study of Bevacizumab and Extended Treatment of Temozolomide in Patients With Recurrent Glioblastoma Multiforme
This is a Phase II, national, multicenter, open-label, non-comparative study to investigate the efficacy and safety of bevacizumab and temozolomide in patients with recurrent glioblastoma multiforme (GBM) after a first treatment…
- Trial name
- NCT01115491
- Testing
- bevacizumab [Avastin], temozolomide
- Where
- 8 sites in Spain
- Volunteers
- 32 people
- Sponsor
- Hoffmann-La Roche
Pediatric Brain Tumor, Diffuse Intrinsic Pontine Glioma
A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG
This research study involves an investigational product: Ad-RTS-hIL-12 given with veledimex for production of human IL-12. IL-12 is a protein that can improve the body's natural response to disease by enhancing the ability of the…
- Trial name
- NCT03330197
- Testing
- Ad-RTS-hIL-12, Oral Veledimex - Arm 1 (Pediatric Brain Tumor), Oral Veledimex - Arm 2 (DIPG)
- Where
- 3 sites in United States
- Volunteers
- 6 people
- Sponsor
- Alaunos Therapeutics
Glioblastoma, Gliosarcoma
Atezolizumab in Combination With Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
This phase I/II trial studies the side effects and how well atezolizumab works in combination with temozolomide and radiation therapy in treating patients with newly diagnosed glioblastoma.
- Trial name
- NCT03174197
- Testing
- Atezolizumab, Radiation Therapy, Temozolomide
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- M.D. Anderson Cancer Center
High Grade Glioma
Antineoplaston Therapy in Treating Children With Recurrent or Refractory High-Grade Glioma
RATIONALE: Current therapies for children with recurrent/progressive high grade gliomas provide very limited benefit to the patient.
- Trial name
- NCT00003535
- Testing
- Antineoplaston therapy (Atengenal + Astugenal)
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Burzynski Research Institute
Glioblastoma Multiforme of Brain, Anaplastic Astrocytoma of Brain
Trial of C134 in Patients With Recurrent GBM
The purpose of this project is to obtain safety information in small groups of individuals, scheduled to receive escalating doses of C134, a cancer killing virus (HSV-1) that has been genetically engineered to safely replicate…
- Conditions
- Glioblastoma Multiforme of Brain, Anaplastic Astrocytoma of Brain, Gliosarcoma of Brain
- Trial name
- C134-HSV-1 (NCT03657576)
- Testing
- C134
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Alabama at Birmingham
Recurrent Childhood Anaplastic Astrocytoma, Recurrent Childhood Brain Stem Glioma
Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors
This phase I/II trial studies lapatinib to see how well it works in treating young patients with recurrent or refractory central nervous system (CNS) tumors.
- Conditions
- Recurrent Childhood Anaplastic Astrocytoma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Ependymoma, Recurrent Childhood Giant Cell Glioblastoma
- Trial name
- NCT00095940
- Testing
- lapatinib ditosylate, therapeutic conventional surgery, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Glioblastoma
Safety, Tolerability and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma
This study of DSF-Cu in combination with TMZ for recurrent GBM will evaluate the antitumor effect in patients who have recurrent GBM.
- Trial name
- NCT03034135
- Testing
- Disulfiram/Copper, Temozolomide (TMZ)
- Where
- 8 sites in United States
- Volunteers
- 23 people
- Sponsor
- Cantex Pharmaceuticals
Glioblastoma Multiforme
Radiation Therapy and Temozolomide Followed by Temozolomide and Poly ICLC in Treating Patients With Newly Diagnosed GBM
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them…
- Trial name
- NCT00262730
- Testing
- poly ICLC, temozolomide, radiation therapy
- Where
- 9 sites in United States
- Volunteers
- 97 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Brain and Central Nervous System Tumors
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00621686
- Testing
- bevacizumab, sorafenib tosylate
- Where
- 204 sites in United States
- Volunteers
- 54 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Recurrent Glioblastoma or Other Glioma Subtypes
A Phase 2 Study of BGJ398 in Patients With Recurrent GBM
This is an open-label non-randomized, multicenter, phase II study of BGJ398 administered to adult patients with histologically confirmed GBM and/or other glioma subtypes with FGFR1-TACC1, FGFR3-TACC3 fusion and/or activating…
- Trial name
- NCT01975701
- Testing
- BGJ398
- Where
- 17 sites in United States, Australia and 4 more
- Volunteers
- 26 people
- Sponsor
- Novartis Pharmaceuticals
Glioblastoma, Gliosarcoma
Phase I/II Trial of AXL1717 in the Treatment of Recurrent Malignant Astrocytomas
This is a single-center, open-label, non-randomized, Phase I/IIa study to investigate the safety, tolerability, and antitumor efficacy of AXL1717 (picropodophyllin as active agent formulated in an oral suspension; PPP) in…
- Conditions
- Glioblastoma, Gliosarcoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma
- Trial name
- AXL1717 (NCT01721577)
- Testing
- AXL1717
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Rush University Medical Center
Glioblastoma Multiforme
Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme
The purpose of this study is to evaluate the objective response rate and 6-month progression-free survival rate of XL184 in subjects with recurrent or progressive glioblastoma multiforme.
- Trial name
- NCT00704288
- Testing
- XL184
- Where
- 8 sites in United States
- Volunteers
- 222 people
- Sponsor
- Exelixis
Glioblastoma Multiforme
A Study of Avastin (Bevacizumab) And Fotemustine in Patients With Recurrent Glioblastoma
This randomized, non-comparative study will evaluate the efficacy and safety of Avastin (bevacizumab) in patients with recurrent glioblastoma.
- Trial name
- NCT01474239
- Testing
- bevacizumab [Avastin], fotemustine
- Where
- 10 sites in Italy
- Volunteers
- 91 people
- Sponsor
- Hoffmann-La Roche
Grade IV Glioma, Grade IV Astrocytoma
Study To Test the Safety and Efficacy of TVI-Brain-1 As A Treatment for Recurrent Grade IV Glioma
TVI-Brain-1 is an experimental treatment that takes advantage of the fact that your body can produce immune cells, called 'killer' white blood cells that have the ability to kill large numbers of the cancer cells that are present…
- Conditions
- Grade IV Glioma, Grade IV Astrocytoma, Glioblastoma Multiforme
- Trial name
- NCT01290692
- Testing
- TVI-Brain-1
- Where
- 4 sites in United States
- Volunteers
- 14 people
- Sponsor
- TVAX Biomedical
Malignant Glioma, Astrocytoma
Nivolumab With DC Vaccines for Recurrent Brain Tumors
Patients will be randomized to one of two treatment arms - Group I and Group II. Group I will receive nivolumab monotherapy until surgical resection, and Group II will receive nivolumab alone and with DC vaccine therapy until…
- Conditions
- Malignant Glioma, Astrocytoma, Glioblastoma
- Trial name
- AVERT (NCT02529072)
- Testing
- nivolumab, DC
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Gary Archer Ph.D.
Glioblastoma Multiforme
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways.
- Trial name
- NCT00892177
- Testing
- bevacizumab, dasatinib
- Where
- 305 sites in United States
- Volunteers
- 144 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Childhood Brain Tumor
Antineoplaston Therapy in Treating Children With Primary Malignant Brain Tumors
RATIONALE: Current therapies for children with primary malignant brain tumors provide limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of…
- Trial name
- NCT00003476
- Testing
- Antineoplaston therapy (Atengenal + Astugenal)
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Burzynski Research Institute
IDH1 Mutation, IDH2 Mutation
BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations
This phase I/II trial studies the side effects and how well BGB-290 and temozolomide work in treating patients with gliomas (brain tumors) with IDH1/2 mutations that have come back.
- Conditions
- IDH1 Mutation, IDH2 Mutation, Recurrent Glioblastoma, Recurrent WHO Grade II Glioma
- Trial name
- NCT03914742
- Testing
- PARP Inhibitor BGB-290, Temozolomide, Therapeutic Conventional Surgery
- Where
- 12 sites in United States
- Volunteers
- 67 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins